Welcome to our dedicated page for Perspective Therapeutics news (Ticker: CATX), a resource for investors and traders seeking the latest updates and insights on Perspective Therapeutics stock.
Perspective Therapeutics, Inc. (NYSE American: CATX) is a radiopharmaceutical development company focused on 212Pb-based theranostic treatments and imaging for cancer. The CATX news page on Stock Titan aggregates company announcements, clinical data updates, conference presentations, financial disclosures, and other material events drawn from press releases and SEC filings.
According to recent communications, Perspective regularly reports interim results from its Phase 1/2a trials of [212Pb]VMT-α-NET in SSTR2-positive neuroendocrine tumors, VMT01 in melanoma patients with MC1R-positive imaging scans, and PSV359 in FAP-α-positive solid tumors. News items often summarize safety findings, investigator-assessed anti-tumor activity, and progress across dose cohorts, along with plans for data presentations at major meetings such as ASCO, ASCO-GI, ESMO, NANETS, and AACR-NCI-EORTC conferences.
Investors and observers can also find updates on corporate presentations, participation in healthcare and biopharma conferences, and periodic business highlights tied to quarterly financial results. Form 8-K filings referenced in the news flow include earnings releases, updated corporate slide decks, and information about executive appointments and employment agreements.
For anyone tracking CATX, this news feed provides a centralized view of Perspective’s clinical development trajectory, manufacturing expansion efforts around its proprietary 212Pb generator, and key corporate developments. Users interested in radiopharmaceutical and oncology catalysts may wish to revisit this page around major medical congresses, scheduled earnings dates, and company-announced business updates.
Perspective Therapeutics (NYSE AMERICAN: CATX) presented initial results from its Phase 1/2a study of [212Pb]VMT01, a MC1R-targeted radiopharmaceutical therapy for melanoma, at the 21st International Congress of the Society for Melanoma Research. Key findings include:
1. Safety: No dose-limiting toxicities observed at 3.0 and 5.0 mCi doses.
2. Efficacy: Prolonged progression-free survival and tumor response in heavily pretreated patients at the 3.0 mCi dose.
3. The trial is progressing with a lower 1.5 mCi dose to optimize immunostimulatory activities, both as monotherapy and in combination with nivolumab.
4. The Safety Monitoring Committee recommended exploring the 1.5 mCi dose level as a single agent and in combination with nivolumab.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, announced that initial results from its Phase 1/2a study of [212Pb]VMT01 have been selected for a poster presentation at the 21st International Congress of the Society for Melanoma Research (SMR). The event will be held on October 10-13, 2024, in New Orleans, Louisiana.
The study, titled “First in Human Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Melanoma (MM),” marks the company's first scientific presentation of clinical data from a company-sponsored study. CEO Thijs Spoor highlighted the ongoing exploration of the optimal dose of [212Pb]VMT01 in metastatic melanoma, both as a single agent and in combination with nivolumab.
Perspective will host a conference call on October 11, 2024, at 9am ET to review the data presented at SMR. Details will be available on the Events page of the company's website.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, announced its participation in two upcoming events: the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit on October 8, 2024, in New York, NY, and the JonesResearch Virtual Radiopharma Day on October 29, 2024.
At the Oppenheimer Summit, Perspective's senior management will participate in two panel discussions: 'The Next Wave of TRTs – Targets, Targeting Technologies and Isotopes' from 9:30 a.m. to 10:30 a.m. ET, and 'Supply Chain Challenges and Controversies: Ac225 Availability, Pb212 Logistics, The Last Mile' from 10:50 a.m. to 11:35 a.m. ET. They will also give a company presentation at 1:30 p.m. ET.
The JonesResearch event will feature a panel format. Webcasts for both events will be accessible live and archived for 90 days on the Perspective website's Investors page.
Perspective Therapeutics (NYSE AMERICAN: CATX) will present updated preclinical data on PSV359 at the 37th Annual Congress of the European Association of Nuclear Medicine (EANM) in Hamburg, Germany, from October 19-23, 2024. The company will showcase several presentations, including:
1. Preclinical evaluation and first-in-human imaging of [203/212Pb]Pb-PSV359, targeting fibroblast activation protein-alpha (FAP).
2. Impact of molar activity on [203Pb]Pb-VMT-α-NET biodistribution in neuroendocrine tumor xenografts.
3. Interim results of 212Pb-VMT-α-NET Targeted Alpha Therapy in metastatic gastro-entero-pancreatic neuroendocrine tumors.
4. Image-guided evaluation of 212Pb-VMT-α-NET in metastatic neuroendocrine tumors.
The presentations will include updated analyses from investigator-led clinical research and preclinical studies, focusing on novel radiopharmaceutical treatments for various cancers.
Perspective Therapeutics (NYSE AMERICAN: CATX) presented updates on its alpha-particle radiopharmaceuticals at the World Molecular Imaging Congress 2024 in Québec, Canada. The company showcased two key presentations:
1. Preclinical evaluation of [203/212Pb]Pb-PSV-359 for imaging and alpha-particle therapy of cancers expressing fibroblast activation protein (FAP). The study demonstrated superior FAP binding affinity, strong tumor uptake, and anti-tumor effects in xenograft models.
2. Customizing chelators for targeted radionuclide therapy using computational modeling. The research highlighted the importance of matching chelators to specific radionuclides for optimal stability and targeted delivery in targeted radionuclide therapy (TRT).
CEO Thijs Spoor expressed satisfaction with the additional data supporting the development of their alpha-particle therapies, emphasizing the need for customized chelators and the favorable safety and efficacy profiles of their FAP-targeting candidate, PSV-359.
Perspective Therapeutics (NYSE AMERICAN: CATX) has received Fast Track Designation from the FDA for its 212Pb VMT01 product, targeting the diagnosis and treatment of unresectable or metastatic melanoma with MC1R tumor expression. This designation expedites development and review processes, offering more frequent FDA interactions and eligibility for accelerated approval, priority review, and rolling review.
The company has completed the observation period for dose-limiting toxicity in seven patients in Cohort 2 of its Phase 1/2a study. Perspective plans to share safety observations with the Safety Monitoring Committee and in a scientific forum later this year. Additionally, they intend to open a VMT01/anti-PD-1 combination cohort, pending institutional review board approval.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focusing on advanced cancer treatments, has announced its participation in three upcoming investor conferences in September 2024. The company's senior leadership will be available for one-on-one meetings with investors at these events:
1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 6 in New York, featuring a fireside chat.
2. 2024 Cantor Global Healthcare Conference on September 17 in New York, also with a fireside chat format.
3. 10th Annual World Medical Innovation Forum on September 24 in Boston, where Perspective will participate in a panel discussion on 'The Biologic Revolution in Radiotherapies'.
Webcasts of these events will be accessible live and archived for 90 days on the company's investor webpage.
Perspective Therapeutics (NYSE AMERICAN: CATX) reported fiscal Q2 2024 results and business highlights. Key points include:
- Completed enrollment of initial Cohort 2 patients in VMT-α-NET and VMT01 clinical trials
- On track to advance multiple pre-IND assets to clinic in 12-18 months
- Progressing on manufacturing infrastructure build-out
- $293 million cash balance expected to fund operations into mid-2026
- Q2 revenue: $0.5 million; R&D expenses: $9.3 million; G&A expenses: $5.5 million
- Net loss: $11.7 million or $0.18 per share
The company is advancing its radiopharmaceutical pipeline and manufacturing capabilities while maintaining a strong cash position to fund ongoing clinical and pre-clinical programs.
Perspective Therapeutics (NYSE AMERICAN: CATX), a pioneering radiopharmaceutical company, has announced its participation in two upcoming investor conferences in August 2024. The company's senior leadership team will be available for one-on-one meetings with investors at both events.
The first conference is the BTIG Virtual Biotechnology Conference, scheduled for August 5-6, 2024, which will be held virtually. The second is the 2024 Wedbush PacGrow Healthcare Conference, taking place in-person in New York, NY on August 13-14, 2024.
At the Wedbush conference, Perspective Therapeutics will also participate in a panel discussion titled 'Nuke 'em From Orbit: Radiotherapy' at 9:30am ET. This engagement highlights the company's focus on advanced treatment applications for cancers throughout the body using radiopharmaceuticals.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focusing on advanced cancer treatments, has announced it will release its Q2 2024 financial results and provide a business update on August 12, 2024, after market close. The company, which specializes in pioneering treatment applications for various cancers, will make the press release available on their website's newsroom section. This announcement signals an important upcoming disclosure for investors and stakeholders, potentially offering insights into the company's financial performance and operational progress in the rapidly evolving field of radiopharmaceuticals.